Cargando…

The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis

BACKGROUND: The relationship between IgG4-related disease (IgG4-RD) and the risk of malignancy is still controversial. This article focused on assessing the risk of cancer in patients with IgG4-RD by meta-analysis. METHODS: We conducted a systematic review of the literature and meta-analysis charact...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Tingfeng, Wu, Yaxian, Liu, Jia, Zhuang, Yanyan, Jin, Xiaoyan, Wang, Lingyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728936/
https://www.ncbi.nlm.nih.gov/pubmed/34986892
http://dx.doi.org/10.1186/s13075-021-02652-2
_version_ 1784626834654101504
author Yu, Tingfeng
Wu, Yaxian
Liu, Jia
Zhuang, Yanyan
Jin, Xiaoyan
Wang, Lingyun
author_facet Yu, Tingfeng
Wu, Yaxian
Liu, Jia
Zhuang, Yanyan
Jin, Xiaoyan
Wang, Lingyun
author_sort Yu, Tingfeng
collection PubMed
description BACKGROUND: The relationship between IgG4-related disease (IgG4-RD) and the risk of malignancy is still controversial. This article focused on assessing the risk of cancer in patients with IgG4-RD by meta-analysis. METHODS: We conducted a systematic review of the literature and meta-analysis characterizing the associated risk of overall malignancy and four site-specific malignancies (pancreas, lung, gastric and lymphoma) in patients with IgG4-RD. A search from 2003 to 2020 was performed using specified terms from PubMed, Embase, Web of Science and SinoMed. Random-effects model analysis was used to pool standardized incidence ratios (SIRs) and 95% confidence intervals (CIs). Subgroup and sensitivity analyses were conducted to clarify the heterogeneity of the included studies. Begg’s funnel plot and Egger’s linear regression test were used to evaluate the bias of the meta-analysis. A P value < 0.05 indicated the existence of publication bias. RESULTS: A total of 10 studies were included in the article. The overall SIR estimates suggested an increased risk of overall cancer in IgG4-RD patients (SIR 2.57 95% CI 1.72–3.84) compared with the general population. The specific SIRs for pancreas and lymphoma were higher than those of the general population in IgG4-RD patients (SIR 4.07 95% CI 1.04–15.92, SIR 69.17 95% CI 3.91–1223.04, respectively). No significant associations were revealed in respiratory and gastric cancer (SIR 2.14 95% CI 0.97–4.75, SIR 0.95 95% CI 0.24–3.95, respectively). Four studies were found to be the major sources of heterogeneity by sensitivity analysis. There was no evidence of publication bias via Egger’s test. CONCLUSION: Compared with the general population, patients with IgG4-RD appear to have a higher risk of overall cancer, especially pancreatic and lymphoma. The risk of lung and gastric cancer was not different between IgG4-RD patients and the general population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02652-2.
format Online
Article
Text
id pubmed-8728936
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87289362022-01-06 The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis Yu, Tingfeng Wu, Yaxian Liu, Jia Zhuang, Yanyan Jin, Xiaoyan Wang, Lingyun Arthritis Res Ther Research Article BACKGROUND: The relationship between IgG4-related disease (IgG4-RD) and the risk of malignancy is still controversial. This article focused on assessing the risk of cancer in patients with IgG4-RD by meta-analysis. METHODS: We conducted a systematic review of the literature and meta-analysis characterizing the associated risk of overall malignancy and four site-specific malignancies (pancreas, lung, gastric and lymphoma) in patients with IgG4-RD. A search from 2003 to 2020 was performed using specified terms from PubMed, Embase, Web of Science and SinoMed. Random-effects model analysis was used to pool standardized incidence ratios (SIRs) and 95% confidence intervals (CIs). Subgroup and sensitivity analyses were conducted to clarify the heterogeneity of the included studies. Begg’s funnel plot and Egger’s linear regression test were used to evaluate the bias of the meta-analysis. A P value < 0.05 indicated the existence of publication bias. RESULTS: A total of 10 studies were included in the article. The overall SIR estimates suggested an increased risk of overall cancer in IgG4-RD patients (SIR 2.57 95% CI 1.72–3.84) compared with the general population. The specific SIRs for pancreas and lymphoma were higher than those of the general population in IgG4-RD patients (SIR 4.07 95% CI 1.04–15.92, SIR 69.17 95% CI 3.91–1223.04, respectively). No significant associations were revealed in respiratory and gastric cancer (SIR 2.14 95% CI 0.97–4.75, SIR 0.95 95% CI 0.24–3.95, respectively). Four studies were found to be the major sources of heterogeneity by sensitivity analysis. There was no evidence of publication bias via Egger’s test. CONCLUSION: Compared with the general population, patients with IgG4-RD appear to have a higher risk of overall cancer, especially pancreatic and lymphoma. The risk of lung and gastric cancer was not different between IgG4-RD patients and the general population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02652-2. BioMed Central 2022-01-05 2022 /pmc/articles/PMC8728936/ /pubmed/34986892 http://dx.doi.org/10.1186/s13075-021-02652-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Yu, Tingfeng
Wu, Yaxian
Liu, Jia
Zhuang, Yanyan
Jin, Xiaoyan
Wang, Lingyun
The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis
title The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis
title_full The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis
title_fullStr The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis
title_full_unstemmed The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis
title_short The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis
title_sort risk of malignancy in patients with igg4-related disease: a systematic review and meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728936/
https://www.ncbi.nlm.nih.gov/pubmed/34986892
http://dx.doi.org/10.1186/s13075-021-02652-2
work_keys_str_mv AT yutingfeng theriskofmalignancyinpatientswithigg4relateddiseaseasystematicreviewandmetaanalysis
AT wuyaxian theriskofmalignancyinpatientswithigg4relateddiseaseasystematicreviewandmetaanalysis
AT liujia theriskofmalignancyinpatientswithigg4relateddiseaseasystematicreviewandmetaanalysis
AT zhuangyanyan theriskofmalignancyinpatientswithigg4relateddiseaseasystematicreviewandmetaanalysis
AT jinxiaoyan theriskofmalignancyinpatientswithigg4relateddiseaseasystematicreviewandmetaanalysis
AT wanglingyun theriskofmalignancyinpatientswithigg4relateddiseaseasystematicreviewandmetaanalysis
AT yutingfeng riskofmalignancyinpatientswithigg4relateddiseaseasystematicreviewandmetaanalysis
AT wuyaxian riskofmalignancyinpatientswithigg4relateddiseaseasystematicreviewandmetaanalysis
AT liujia riskofmalignancyinpatientswithigg4relateddiseaseasystematicreviewandmetaanalysis
AT zhuangyanyan riskofmalignancyinpatientswithigg4relateddiseaseasystematicreviewandmetaanalysis
AT jinxiaoyan riskofmalignancyinpatientswithigg4relateddiseaseasystematicreviewandmetaanalysis
AT wanglingyun riskofmalignancyinpatientswithigg4relateddiseaseasystematicreviewandmetaanalysis